Multiplex analysis of expression of three IFNbeta-induced genes in antibody-positive MS patients

Neurology. 2006 Feb 14;66(3):444-6. doi: 10.1212/01.wnl.0000196467.71646.72.

Abstract

Some interferon beta (IFNbeta)-treated patients with multiple sclerosis develop antibody-mediated decreased bioactivity with resultant loss of therapeutic effect. The authors developed real-time multiplex reverse transcriptase PCR to measure expression of three IFNbeta-inducible genes to directly assess IFNbeta bioactivity in patients with neutralizing antibodies (NAbs). The three genes responded in tandem. Correlation of NAb level with bioactivity at low/moderate NAb levels was poor, indicating that for such patients, direct measurement of IFNbeta bioactivity is most reliable.

Publication types

  • Comparative Study

MeSH terms

  • 2',5'-Oligoadenylate Synthetase / genetics
  • Adjuvants, Immunologic / therapeutic use*
  • Case-Control Studies
  • GTP-Binding Proteins / genetics
  • Gene Expression
  • Gene Expression Regulation / drug effects*
  • Humans
  • Interferon-beta / therapeutic use*
  • Multiple Sclerosis / drug therapy
  • Multiple Sclerosis / genetics*
  • Multiple Sclerosis / immunology*
  • Myxovirus Resistance Proteins
  • Neutralization Tests*
  • Oxidoreductases Acting on CH-CH Group Donors
  • Proteins / genetics
  • Reverse Transcriptase Polymerase Chain Reaction

Substances

  • Adjuvants, Immunologic
  • Myxovirus Resistance Proteins
  • Proteins
  • Interferon-beta
  • Oxidoreductases Acting on CH-CH Group Donors
  • RSAD2 protein, human
  • 2',5'-Oligoadenylate Synthetase
  • GTP-Binding Proteins